Abstract
Introduction: Luspatercept is approved for patients with very low-to intermediate-risk myelodysplastic syndrome (MDS). Dosing is based on pre-dose hem......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
